Dr. Grégoire served as President of the Human Genetic Therapies division of Shire plc, a public biopharmaceutical company, from 2007 to 2013 and from 2005 to 2008 she served as a director of IDM Pharma, Inc., a public biotechnology company that now operates as a subsidiary of Takeda Pharmaceuticals, including serving as its Executive Chair from August 2006 to October 2007. From 2004 to 2005, Dr. Grégoire served as President, Chief Executive Officer and Executive Member of the board of directors of GlycoFi, Inc., a private biotechnology company. Prior to that, Dr. Grégoire was employed in several key operating and regulatory affairs positions at Biogen, Inc. (now known as Biogen Idec Inc.) and Merck & Co.
Dr. Grégoire currently serves on the board of Novo Nordisk and EIP Pharma. Dr. Grégoire holds a Bachelor of Science degree from Laval University and a Doctoral degree from the State University of New York at Buffalo.
Dr. Grégoire provides the board with a depth of experience in the management of commercial operations, manufacturing and regulatory affairs within the biotechnology industry, both domestically and internationally. Her extensive background gained over the course of almost thirty years of leadership positions with both public and private companies, as well as her current and past service on the boards of other public companies, will provide the board with valuable guidance in overseeing the strategic direction of the Company.
How do I contact Sylvie Gregoire?
Has Sylvie Gregoire been buying or selling shares of Revvity?
Sylvie Gregoire has not been actively trading shares of Revvity during the last quarter. Most recently, Sylvie Gregoire sold 5,000 shares of the business's stock in a transaction on Tuesday, July 6th. The shares were sold at an average price of $155.57, for a transaction totalling $777,850.00. Learn More on Sylvie Gregoire's trading history.
Who are Revvity's active insiders?
